Back to top
more

Avinger (AVGR)

(Delayed Data from NSDQ)

$0.78 USD

0.78
79,430

0.00 (0.00%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $0.79 +0.01 (1.28%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Avinger (AVGR) Launches Pantheris LV to Boost PAD Treatment

by Zacks Equity Research

Avinger (AVGR) fully launches Pantheris LV, the first image-guided atherectomy system for large vessels, thus enhancing peripheral artery disease treatment with advanced technology.

Avinger (AVGR) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Avinger (AVGR) delivered earnings and revenue surprises of -555.81% and 27.57%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Steris (STE) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Steris (STE) delivered earnings and revenue surprises of 1% and 1.47%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Are Medical Stocks Lagging Avinger (AVGR) This Year?

by Zacks Equity Research

Here is how Avinger (AVGR) and Ayr Wellness Inc. (AYRWF) have performed compared to their sector so far this year.

Asensus Surgical (ASXC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Asensus Surgical (ASXC) delivered earnings and revenue surprises of -40% and 2.09%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

IQVIA Holdings (IQV) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

IQVIA (IQV) delivered earnings and revenue surprises of 2.83% and 1.22%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

TransMedics (TMDX) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

TransMedics (TMDX) delivered earnings and revenue surprises of 800% and 16.24%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Avinger (AVGR) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Avinger (AVGR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Are Medical Stocks Lagging Edwards Lifesciences (EW) This Year?

by Zacks Equity Research

Here is how Edwards Lifesciences (EW) and Avinger (AVGR) have performed compared to their sector so far this year.

Avinger (AVGR) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Avinger (AVGR) delivered earnings and revenue surprises of -2.46% and 24.29%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Intuitive Surgical, Inc. (ISRG) Q3 Earnings Surpass Estimates

by Zacks Equity Research

Intuitive Surgical, Inc. (ISRG) delivered earnings and revenue surprises of 3.55% and 1.37%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Avinger (AVGR) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Avinger (AVGR) delivered earnings and revenue surprises of -20.41% and 11.26%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Codex DNA (DNAY) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Codex DNA (DNAY) delivered earnings and revenue surprises of 1.96% and 22.94%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Delcath Systems, Inc. (DCTH) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Delcath Systems, Inc. (DCTH) delivered earnings and revenue surprises of -34.09% and 36.49%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

CVRx (CVRX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

CVRx (CVRX) delivered earnings and revenue surprises of 0% and 6.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Avinger (AVGR) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Avinger (AVGR) delivered earnings and revenue surprises of -92.56% and 0.11%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

AxoGen (AXGN) delivered earnings and revenue surprises of -17.65% and 2%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Avinger (AVGR) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Avinger (AVGR) delivered earnings and revenue surprises of 0% and 4.48%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Neuronetics (STIM) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Neuronetics (STIM) delivered earnings and revenue surprises of 12.12% and 2.40%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

LENSAR, Inc. (LNSR) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

LENSAR, Inc. (LNSR) delivered earnings and revenue surprises of 31.67% and 31.87%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Natus Medical (NTUS) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Natus Medical (NTUS) delivered earnings and revenue surprises of 6.82% and 0.51%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Tactile Systems Technology (TCMD) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Tactile Systems Technology (TCMD) delivered earnings and revenue surprises of -566.67% and 6.03%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Avinger (AVGR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Avinger (AVGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Avinger (AVGR) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Avinger (AVGR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Avinger (AVGR) Upgraded to Buy: Here's Why

by Zacks Equity Research

Avinger (AVGR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).